BioBigBird: A Sparse Attention Model for Long-Range Dependency Processing in Biomedical Text
Organizations: Wadhwani School of Data Science and AI, Indian Institute of Technology Madras, Chennai, India
Abstract
While domain-specific Large Language Models (LLMs) have encoded vast biomedical knowledge, their limited context windows often hinder a deep understanding of nuanced relationships within and across texts. To address this limitation, we introduce BioBigBird, a bidirectional language model pre-trained on extensive biomedical literature and clinical data, specifically designed to handle long-range dependencies. BioBigBird leverages a sparse attention mechanism to process sequences up to 4096 tokens, and its training incorporates a multi-stage process to mitigate noise from the large-scale pre-training corpus. We further enhance its performance by employing a multi-task learning (MTL) framework that jointly optimizes for Named Entity Recognition and Relation Extraction. Comprehensive evaluations on the BLURB benchmark reveal that our MTL-enhanced BioBigBird achieves highly competitive results against state-of-the-art models. Our work contributes an effective methodology for developing powerful, long-context language models for specialized domains, demonstrating the value of extended sequence processing for complex text analysis. Our models are publicly available at https://huggingface.co/collections/bisectgroup/biobigbird.
Figures & tables
| Dataset | Disk Space | # Samples | # Tokens |
|---|---|---|---|
| PubMed Articles | 80 GB | 2.3 M | 10 B |
| PubMed Abstracts | 31 GB | 42 M | 10 B |
| MIMIC-III | 3.5 GB | 2 M | 2 B |
| Dataset | Disk Space | # Samples |
|---|---|---|
| Raw Articles | 300 GB | 4.7 M |
| Pre-processed Articles | 80 GB | 2.3 M |
| Dataset | Entity Type |
|---|---|
| NCBI Disease ( Doğan et al., 2014 ) | Disease |
| BC5CDR ( Li et al., 2016 ) | Disease |
| BC5CDR ( Li et al., 2016 ) | Drug/Chem. |
| BC4CHEMD ( Krallinger et al., 2014 ) | Drug/Chem. |
| BC2GM ( Smith et al., 2008 ) | Gene |
| JNLPBA ( Collier and Kim, 2004 ) | Biological Molecules |
| Dataset | Entity Type |
|---|---|
| GAD ( Bravo et al., 2015 ) | Gene-disease |
| DDI ( Herrero-Zazo et al., 2013 ) | Drug-drug |
| ChemProt ( Krallinger et al., 2017 ) | Protein-chemical |
| PubMedBERT | BioLinkBERT | BioLinkBERT | BioBigBird | |
| ( Gu et al., 2021 ) | ( Yasunaga et al., 2022 ) | ( Yasunaga et al., 2022 ) | Stage 3 | |
| Base (110 M) | Base (110 M) | Large (340 M) | (113 M) | |
| BC5-chem ( Li et al., 2016 ) | 93.33 | 93.75 | 94.04 | 94.06 |
| BC5-disease ( Li et al., 2016 ) | 85.62 | 86.10 | 86.39 | 85.18 |
| NCBI-disease ( Doğan et al., 2014 ) | 87.82 | 88.18 | 88.76 | 85.59 |
| BC2GM ( Smith et al., 2008 ) | 84.52 | 84.90 | 85.18 | 84.37 |
| PubMedBERT | BioLinkBERT | BioLinkBERT | BERN-2 | BioBigBird | BioBigBird | |
| ( Gu et al., 2021 ) | ( Yasunaga et al., 2022 ) | ( Yasunaga et al., 2022 ) | ( Sung et al., 2022 ) | Stage 3 | MT-Stage 3 | |
| Base (110 M) | Base (110 M) | Large (340 M) | (365 M) | (113 M) | (120 M) | |
| BC5-chem ( Li et al., 2016 ) | 93.33 | 93.75 | 94.04 | N/A | 94.06 | 95.07 |
| BC5-disease ( Li et al., 2016 ) | 85.62 | 86.10 | 86.39 | N/A | 85.18 | 90.36 |
| NCBI-disease ( Doğan et al., 2014 ) | 87.82 | 88.18 | 88.76 | 88.6 | 85.59 | 93.67 |
| BC2GM ( Smith et al., 2008 ) | 84.52 | 84.90 | 85.18 | 83.7 | 84.37 | 91.85 |